Download PDF
Thromb Haemost 1978; 39(01): 061-068
DOI: 10.1055/s-0038-1646655
Original Article
Schattauer GmbH Stuttgart

Biochemical Changes Noted during Intermittent Administration of Streptokinase

M Verstraete
The Center for Thrombosis and Vascular Research, Medical Research Department, University of Leuven, Belgium
,
J Vermylen
The Center for Thrombosis and Vascular Research, Medical Research Department, University of Leuven, Belgium
,
J Schetz
The Center for Thrombosis and Vascular Research, Medical Research Department, University of Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 06 March 1997

Accepted 22 June 1997

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

An intermittent dosage scheme of streptokinase (standard initial dose 600,000 units SK infused over 30 min and repeated injections of 250,000 units SK at 24 hr intervals) was applied during 4 days in 9 patients with chronic obliterative arterial disease and in 8 patients with venous occlusion.

Each dose of streptokinase produced an immediate fall in plasminogen to 17 % (SEM 5.1) of the initial value, the level then rose to 50 % (SEM 5.4) within 24 hr. Lowered levels of antiplasmin and fibrinogen (both less than 40% of the initial values) were maintained. This safe level of fibrinogen was maintained despite brief but high peaks of plasmin activity after each injection of SK. A parallel increase of the thrombin time and the fibrin(ogen) degradation products was obtained following each infusion. No bleeding was observed. The relative therapeutic effect of intermittent infusions of streptokinase has still to be compared with the continuous administration of streptokinase in controlled clinical trials.

 

  • References

  • 1 Amery A. 1969. Activation of the human plasma fibrinolytic system by streptokinase. Therapeutic application in thromboembolic occlusions of the limb arteries and in myocardial infarction.. Acco; Leuven: Belgium:
    Google Scholar
  • 2 Amery A, Deloof W, Vermylen J, Verstraete M. 1970; Outcome of recent thromboembolic occlusions of limb arteries treated with streptokinase. British Medical Journal 11: 639
    PubMedGoogle Scholar
  • 3 Astrup P, Mullertz S. 1952; The fibrin plate method for estimating fibrinolytic activity. Archives of Biochemistry and Biophysics 40: 346
    CrossrefPubMedGoogle Scholar
  • 4 Benda L. 1973; Influence of streptokinase on blood rheology and coagulation. Postgraduate Medical Journal August, Suppl 129
    PubMedGoogle Scholar
  • 5 Blomback B, Blomback M. 1956; Purification of human and bovine fibrinogen. Arkiv. Kemi 10: 415
    PubMedGoogle Scholar
  • 6 Chesterman CN, Allington MJ, Sharp AA. 1972; Relationship of plasminogen activator to fibrin. Nature (London) – New Biology 238: 15
    PubMedGoogle Scholar
  • 7 Clarke HGM, Freeman T. 1968; Quantitative Immunoelectrophoresis of human serum proteins. Clinical Sciences 35: 403
    PubMedGoogle Scholar
  • 8 Collen D, De Cock F, Edy J. 1976; Identification and some properties of a new fast-reacting plasmin inhibitor in human blood. European Journal of Biochemistry 69: 209
    CrossrefPubMedGoogle Scholar
  • 9 Conard J, Samama M. 1973; Laboratory control of SK therapy. Thrombosis et Diathesis Haemorrhagica Suppl. 56: 191
    PubMedGoogle Scholar
  • 10 De Vreker RA. 1965; A technique for routine evaluation of plasminogen in humans during streptokinase therapy. Acta haematologica (Basel) 34: 305
    CrossrefPubMedGoogle Scholar
  • 11 Fletcher AP, Sherry S, Alkjaersig N, Smyrniotes FE, Jick S. 1965; The maintenance of a sustained thrombolytic state in man II: clinical observations in patients with myocardial infarction and other thromboembolic disorders. Journal of clinical Investigations 38: 1111
    PubMedGoogle Scholar
  • 12 Gaffney PJ. 1968; The molecular and functional condition of plasma fibrinogen during thrombolytic therapy with streptokinase (SK). Thrombosis Research 2: 105
    PubMedGoogle Scholar
  • 13 Heikinheimo R. 1959; Fibrinolysis by minidosage. Current Therapeutic Research 10: 382
    PubMedGoogle Scholar
  • 14 Heikinheimo R, Ruosteenoja R. 1971; Further experience with “minidosage” in fibrinolytic treatment. Current Therapeutic Research 13: 444
    PubMedGoogle Scholar
  • 15 Johnson AJ, McCarty WR. 1959; The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. Journal of clinical Investigation 38: 1627
    CrossrefPubMedGoogle Scholar
  • 16 Laurell CB. 1966; Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Analytical Biochemistry 15: 45
    CrossrefPubMedGoogle Scholar
  • 17 Lunden R. 1974. Biochemical considerations on streptokinase administration. Workshop on streptokinase. Stockholm: May 2nd
    Google Scholar
  • 18 Merskey CP, Lalezari P, Johnson AJ. 1969; A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proceedings of the Society of Experimental Biology 131: 871
    PubMedGoogle Scholar
  • 19 Quick AJ. 1935; The prothrombin in hemophilia and in obstructive jaundice. Journal of Biological Chemistry 109: 73
    PubMedGoogle Scholar
  • 20 Vermylen C, Verstraete M. 1960; Antithrombin V: Critical evaluation of its assessment and properties. Thrombosis et Diathesis Haemorrhagica 5: 267
    PubMedGoogle Scholar
  • 21 Vermylen C, de Vreker RA, Verstraete M. 1963; A quick quantitative enzymatic fibrinogen assay method: the fibrin polymerization time (FPT). Clinica et chimica Acta 8: 428
    PubMedGoogle Scholar
  • 22 Verstraete M, Vermylen J, Amery A, Vermylen C. 1966; Thombolytic therapy with streptokinase using a standard dosage scheme. British Medical Journal 1: 454
    CrossrefPubMedGoogle Scholar